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Abstract
Tissue plasminogen activator (tPA) is the only FDA-approved treatment for reperfusing ischemic strokes. But widespread
use of tPA is still limited by fears of inadvertently administering tPA in patients with intracerebral hemorrhage (ICH).
Surprisingly, however, the assumption that tPA will worsen ICH has never been biologically tested. Here, we assessed the
effects of tPA in two models of ICH. In a mouse model of collagenase-induced ICH, hemorrhage volumes and neurological
deficits after 24 hrs were similar in saline controls and tPA-treated mice, whereas heparin-treated mice had 3-fold larger
hematomas. In a model of laser-induced vessel rupture, tPA also did not worsen hemorrhage volumes, while heparin did.
tPA is known to worsen neurovascular injury by amplifying matrix metalloproteinases during cerebral ischemia. In contrast,
tPA did not upregulate matrix metalloproteinases in our mouse ICH models. In summary, our experimental data do not
support the assumption that intravenous tPA has a deleterious effect in acute ICH. However, due to potential species
differences and the inability of models to fully capture the dynamics of human ICH, caution is warranted when considering
the implications of these findings for human therapy.
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Introduction
Stroke is a major cause of death and long-term disability
worldwide. For ischemic strokes, clots in the brain can be dissolved
with recombinant tissue plasminogen activator (tPA) [1]. Timing
of tPA application is critically important. The sooner patients
receive tPA and reperfuse, the better the odds ratio for improved
outcomes. However, in current clinical practice, performing
a brain scan is considered indispensable prior to tPA therapy in
order to rule out patients with intracerebral hemorrhage (ICH)
[2]. This induces a substantial time-to-treatment delay, as tPA
cannot be given at the patients’ home or in the ambulance as is the
case for myocardial infarction [3].
Of course, tPA is not completely benign. Many experimental
studies now show that excessive tPA can amplify excitotoxic
neuronal death and promote blood brain barrier injury [4,5]. But
it is important to remember that, even after factoring in rates of
complications and side effects, tPA is still clinically effective when
given to the right patients at the right time. Yet, tPA usage is still
limited to less than 5% of all ischemic strokes today, more than 10
years after FDA approval. From a clinical and practical
perspective, the fear of inadvertently administering tPA in ICH
is a major factor that limits the use of this important therapy. The
widespread assumption that tPA therapy would worsen ICH seems
intuitive, but lacks scientific validation. Here, we tested the effects
of intravenous tPA therapy in different experimental models of
ICH in mice.
Results
An in vitro activity assay confirmed that the recombinant
human tPA dosing used in our experiments was able to convert
mouse plasminogen into active plasmin, the enzyme responsible
for clot lysis (Fig. 1A) [6]. Enzyme activity was further confirmed
in vivo using a standard rat model of thromboembolic focal
cerebral ischemia [7]. Homologous blood clots were intraluminally
placed into the middle cerebral artery, and then rats were treated
with either saline or 10 mg/kg of tPA at 1 hr post occlusion. Laser
Doppler flowmetry confirmed that tPA effectively restored
cerebral blood flow (Fig 1B).
The first model of ICH involved the standard and widely-used
stereotactic injection of collagenase type VII-S (0.2 U) into mouse
striatum to provoke ICH. Consistent with previous work [8,9],
ICH began within 30 min after collagenase injection, and
hematoma development was well underway by 1 hr (see
Methods and Fig. 2A). At 30 min after ICH induction, mice
were blindly and randomly assigned to one of 3 treatment groups:
saline controls (500 ml, n=15), tPA (10 mg/kg in 500 ml saline,
n=15), or the anticoagulant heparin (used as a positive control,
100 U/kg in 500 ml saline, n=4). Treatments were infused over
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induction, hematoma volumes were assessed using a photometric
assay. Surprisingly, hematoma volumes were not different between
saline controls (mean6SD 7.563.4 ml) and tPA-treated mice
(7.663.5 ml), but heparin significantly worsened hemorrhage
(19.868.8 ml, one-way ANOVA between group differences
p,0.001, post-hoc saline vs. tPA p=1.000, saline vs. heparin
p,0.001, tPA vs. heparin p,0.001, Fig. 2B). Mortality rate was
0/15 in saline mice, 2/15 in tPA mice, and 2/4 in heparin mice.
The two tPA-treated mice that died had pronounced bleeding at
the surgical areas (head, neck), but ICH volume was not increased
(2.6 and 7.3 ml, respectively). Most likely, death resulted from
extracerebral bleeding complications. In contrast, the dead
heparin mice had extensive ICH volumes (33.0 and 14.7 ml).
The functional impact of ICH, assessed by means of a standard
hanging wire test, was not different between saline- and tPA-
treated mice (Fig. S1). Because this result was somewhat
surprising, a second independent study was initiated to confirm
these findings. Using different batches of tPA and collagenase, 24
ICH mice were randomized to saline controls (500 ml, n=8), tPA
(10 mg/kg in 500 ml saline, n=8), or heparin (100 U/kg in 500 ml
saline, n=8). Once again, treatments were infused over 30 min
via a jugular vein catheter. Three mice had to be excluded due to
catheter complications (rupture of jugular vein). At 24 hrs,
hematoma volumes were generally larger than in the first
experimental series, likely due to variations of enzyme activity
between different collagenase batches. However, the same pattern
of results was obtained between groups. Controls (mean6SD
16.467.4 ml) and tPA-treated mice (18.564.3 ml) had similar
hematoma volumes, whereas heparin-treated mice had larger
bleeds (27.465.1 ml, one-way ANOVA between group differences
p=0.004, post-hoc saline vs. tPA p=1.000, saline vs. heparin
p=0.005, tPA vs. heparin p=0.033, Fig. 2C). Mortality rate was
2/7 in saline mice, 4/6 in tPA mice, and 7/8 in heparin mice.
To further confirm these findings, we also tested tPA injection at
a later time point (i.e., between 4 and 4.5 hrs after ICH induction
when more clot formation in the extravasated blood has occurred).
Following the same experimental protocol as above, no difference
was found between mice treated with tPA (mean6SD 8.265.8 ml)
and saline (7.962.7 ml, n=8 per group, t-test p=0.882),
suggesting that no re-bleeding was induced by means of the tPA
injection at this later time point after the initiation of ICH.
To rule out the possibility that our findings were caused by
artifacts specific to the collagenase model of ICH, we repeated
these experiments using an independent ICH model, involving
laser-mediated rupture of cerebral blood vessels under in vivo
imaging (see Methods for details). Cranial windows were
implanted in mice (n=11). Five days later, bleeding was induced
in one to four penetrating arterioles per mouse by injuring the
targeted endothelium with tightly-focused femtosecond laser pulses
[10]. This technique produces hematoma volumes about 20,000
times smaller than the ICH model, but this model provides
a powerful way to image, in real time, the development of vascular
rupture and bleeding in vivo. During the production of these
hemorrhages, animals received intravenous saline (n=4), tPA
(n=4), or heparin (n=3), as described above. Using in vivo two-
photon excited fluorescence microscopy, we found no difference in
the size of the red blood cell (RBC)-filled microhemorrhage core
or the surrounding blood plasma-filled region between saline and
tPA-treated mice (Fig. 3A–C). In contrast, hemorrhages pro-
duced while infusing heparin were significantly larger than saline
controls (ANOVA, post hoc; RBC diameter: p,0.001; plasma
extravasation diameter: p=0.019). We identified 18 of the
femtosecond laser-induced intracerebral microhemorrhages in
post-mortem tissue sections. Across all treatments, we found that,
in addition to making a spherical hematoma, RBCs spread
vertically along the perivascular space surrounding the targeted
penetrating arteriole (Fig. S2a–c). Blood plasma, however, was
able to diffuse through the parenchyma tissue and exhibited a more
extended spatial pattern (Fig. S2d–f). We consistently observed
that heparin treatment led to a larger spherical RBC-filled volume
compared to saline and tPA treatments (Fig. S2c and S2f).
Our results showed that tPA did not worsen bleeding in two
independent animal models of ICH. In order to further assess the
specificity of our findings, we next tested tPA in a pathophysiolo-
gically different type of brain injury, subarachnoid hemorrhage
(SAH). Following a standard model, SAH was induced in mice by
perforating the left anterior cerebral artery using a blunted nylon
suture [11]. Thirty min later, saline or tPA was infused, as
described above. Subarachnoid blood volume was quantified at
24 hrs using the same photometric assay as before. SAH blood
volumes were significantly larger in tPA-treated animals compared
to saline controls (mean6SD 20.0610.8 vs. 8.363.5 ml,
p=0.010, t-test) (Fig. 4). SAH severity was clearly worsened by
Figure 1. tPA activity measures. (A) Human tPA but not saline
activates mouse plasminogen. In this assay, tPA converts plasminogen
to plasmin, then plasmin converts D-Val-Leu-Lys-7-Amino-4-Methylcou-
marin to a fluorescent product, which was measured over 1 hr at 5
minute intervals using a fluorescence plate reader. Data are provided in
arbitrary fluorescence units (A.U.). Data are mean6SEM, 3 measures per
group and time point. (B) Thrombolytic activity of tPA was proven in-
vivo in a standard model of thromboembolic middle cerebral artery
occlusion in rats. tPA restored regional cerebral blood flow (rCBF) more
rapidly than saline. Data are mean6SEM, 4 animals per group.
doi:10.1371/journal.pone.0054203.g001
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PLOS ONE | www.plosone.org 2 February 2013 | Volume 8 | Issue 2 | e54203Figure 2. Collagenase-induced ICH volumes are not increased by administration of i.v. tPA. (A) Brain sections showing hematoma at
30 min, 60 min and 24 hrs after ICH induction. ICH starts to occur within 30 min and has largely developed by 1 hr. (B) Hematoma volumes at 24 hrs
after ICH induction (mean6SD). tPA did not alter hematoma sizes, but heparin significantly worsened ICH as compared to saline and tPA treatment.
(C) Results of the reconfirmation study. No difference was observed between saline and tPA mice, but heparin significantly increased ICH volume
(mean6SD) as compared to saline and tPA treatment.
doi:10.1371/journal.pone.0054203.g002
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to 0 out of 7 saline animals. Functional outcome assessed on an
ordinal scale was also significantly worsened in tPA-treated SAH
mice (p=0.014, Mann Whitney U-test).
It is known that tPA can exacerbate neurovascular injury during
cerebral ischemia. Indeed, many labs have shown that adminis-
tration of tPA worsens blood brain barrier damage during
reperfusion injury in ischemic stroke, in part by amplifying matrix
metalloproteinases (MMPs) [12,13]. Hence, we hypothesized that
the different outcomes after tPA application in focal cerebral
ischemia versus ICH may be accompanied by different responses
in MMP activity. Mice were subjected to either transient focal
cerebral ischemia or collagenase-induced ICH and randomized
into saline or tPA groups. For the ischemia group, the middle
cerebral arteries were occluded with intraluminal sutures for 3 hrs,
then mice were treated with saline or 10 mg/kg tPA intravenously,
followed by reperfusion via withdrawal of the occluding sutures.
Brains were extracted and MMP levels were measured after 3 hrs
of reperfusion. For the ICH group, mice were treated with saline
or 10 mg/kg tPA intravenously at 3 hrs after collagenase injection,
Figure 3. Femtosecond laser-induced cortical microhemorrhage volumes are not increased by i.v. administration of tPA. (A) Two-
photon excited fluorescence in vivo image projections of fluorescently-labeled blood plasma spanning a 20 mm depth centered at the hemorrhage
origin. Image stacks are shown before and after rupturing the wall of a single penetrating arteriole using tightly focused femtosecond laser pulses.
Representative examples from the three different intravenous infusion groups (saline, tPA, heparin) are shown. Extravasated plasma is visualized by
diffuse fluorescence and can be seen in the post hemorrhage images in a halo surrounding the target vessel. The dark core immediately adjacent to
the target vessel is filled with red blood cells. Post-hemorrhage (B) red blood cell (RBC) and (C) blood plasma extravasation diameters (mean6SEM)
are shown for the three treatments: saline (n=9 microhemorrhages), tPA (n=11), and heparin (n=10). No difference was found between the saline
and tPA group, but heparin significantly increased both red blood cell and blood plasma extravasation diameters.
doi:10.1371/journal.pone.0054203.g003
Figure 4. Treatment with tPA worsened subarachnoid hemor-
rhage. Blood volumes at 24 hrs after SAH induction (mean6SEM) are
provided. tPA significantly increased SAH blood volume (tPA, n=6;
saline, n=7).
doi:10.1371/journal.pone.0054203.g004
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expected, MMP-2 and MMP-9 levels were elevated in injured
ipsilateral brain tissue in all ischemia and hemorrhage mice. In
focal cerebral ischemia, MMP levels were significantly higher in
tPA-treated mice compared to saline-treated mice. However, tPA
did not amplify MMPs in brains from ICH mice (Fig. 5A–B, Fig.
S3).
Discussion
Our results in two different mouse models of ICH suggest that
intravenous tPA application during the phase of hematoma
formation does not increase intracerebral hemorrhage volume.
Our findings stand in sharp contrast to the widespread – but so far
unproven – assumption that tPA would enlarge hematomas if
inadvertently given to patients with acute ICH. Unlike tPA, the
anticoagulant heparin significantly increased intracerebral hem-
orrhage volume. This positive control demonstrates that both of
our ICH models are able to detect hematoma enlargement if it
occurs. And the results are consistent with our previous findings
that another anticoagulant, warfarin, exacerbates hemorrhage in
ICH mice as compared to anticoagulation-naı ¨ve controls [8].
Although we did not quantify absolute fibrinolytic activity in
comparison to reference standards, we showed that our tPA
preparations were thrombolytically active, both in-vivo and in-
vitro.
From a mechanism standpoint, the massive hematoma
enlargement after heparin therapy suggests that drugs were
administered prior to definitive clot formation. Unlike warfarin
and heparin, tPA has no effect on primary hemostasis and does not
delay initial coagulation. But as an activator of the fibrinolytic
cascade, tPA increases the risk of re-bleeding from previously
hemostatic stable areas [14]. So tPA could theoretically worsen
intracerebral bleeding. On the other hand, the fibrinolytic activity
of tPA is highly dependent on parameters such as clot structure.
For example, platelet-rich thrombi are much less susceptible to
tPA dissolution compared with erythrocyte-rich thrombi, mainly
due to the release of platelet-derived plasminogen activator
inhibitor [15]. Intracerebral hematomas consist of whole blood
containing large amounts of platelets so it is possible that these
structures may be more tPA-resistant. Another possible explana-
tion for our finding is that the ICH clots surrounding ruptured
brain blood vessels are heterogeneous and larger than singular
intra-arterial thrombi in ischemic stroke [9]. Standard doses of tPA
may not be able to dissolve significant parts of the coagulated
hematoma in order to induce re-bleeding. Furthermore, ICH may
be stabilized by the counterpressure of surrounding brain tissue,
which limits hematoma expansion. Elevated pressure in the brain
areas near the hematoma may even prevent systemic intravenously
administered tPA from reaching the initial sites of vessel rupture.
Our finding that tPA does not amplify MMP-2 and MMP-9 in
ICH potentially suggests that this drug is not activated by
a parenchymal (i.e. extra-arterial) clot formation in the same
way as it is activated by an intraluminal thrombus in ischemic
stroke [16]. However, there might be other members of the MMP
family involved in the pathophysiologic cascades following ICH
that are activated by tPA treatment [17]. Brain edema was not
measured in our study. But tPA was found to aggravate brain
edema if injected into the ventricles in the case of ICH with
ventricular extension (in this setting, tPA injection is intended to
restore the drainage of the cerebrospinal fluid) [18,19]. Neverthe-
less, it is unlikely that differences in edema formation between tPA-
and saline-treated mice have influenced our main outcome
Figure 5. Gelatin zymography of MMP responses. (A) Representative zymogram gels showing MMP-2 and MMP-9 levels in brain homogenates
derived from mice subjected to focal cerebral ischemia (induced by middle cerebral artery occlusion, MCAO) or primary ICH mice. (B) Quantified
densitometry of the zymogram results (arbitrary units normalized to constant loading of MMP standards). After 3 hrs of focal cerebral ischemia
followed by 3 hrs reperfusion, tPA significantly amplified MMP-2 and MMP-9 levels. In contrast, there were no differences in MMPs in saline versus
tPA-treated mice after ICH.
doi:10.1371/journal.pone.0054203.g005
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formation occur sequentially rather than simultaneously.
In contrast to ICH, our results clearly show that tPA
dramatically increases blood volume in SAH. Pathophysiologi-
cally, SAH results from the rupture of a larger intracranial artery
in the subarachnoid space outside the brain. Blood extravasation is
immediately followed by the induction of the coagulation cascade,
leading to the formation of a fibrin-rich clot in the vessel wall [20].
In ischemic stroke, tPA is able to dissolve thrombi in arteries of
similar diameter [1]. Thus, it is conceivable that tPA applied in
acute SAH is able to reach the site of the initial vessel rupture,
thereby dissolving newly-formed arterial clots. Any re-bleeding
would then easily expand into the subarachnoid space.
What is extremely important is that our results must be
distinguished from the fact that tPA therapy increases the risk of
hemorrhagic transformation after ischemic stroke [21]. The
mechanisms involved in primary ICH are different from those
that underlie hemorrhagic transformation and reperfusion injury
after ischemia. Hemorrhagic transformation during reperfusion
injury is now known to be related to excitotoxic effects of tPA and
neurovascular upregulation of MMPs [5,12,13], rather than the
re-bleeding of a previously terminated hematoma. tPA may not
worsen ICH, but this is different from potential deleterious effects
of tPA during cerebral ischemia and reperfusion. Our present data
support this idea. tPA seems to amplify MMPs during cerebral
ischemia-reperfusion but not during ICH formation.
We performed an extensive literature research, but did not find
clinical or experimental data targeted to explore the effects of tPA
on hematoma volume in the acute phase of ICH. However,
a recent study on memantine as an adjunctive therapy to tPA in
ischemic stroke also analyzed a group of mice subjected to
collagenase ICH. [22] Whereas a bolus injection of tPA (10 mg/
kg) 30 min after ICH induction increased hematoma size on MRI
scans, the combined administration of tPA and memantine did not
change ICH as compared to controls. As memantine is a NMDA-
antagonist which does not reduce the thrombolytic activity of tPA
itself, these findings are worthwhile to be further explored in the
context of the present study. In addition, we found one more study
that explored tPA administration in a guinea pig model of
collagenase ICH. [23] In this work, a dose-dependent increase of
hematoma volumes was observed. The results of the higher dose
groups stand in apparent contrast to our findings and need further
evaluation.
One should be cautious when transferring our experimental
findings to the clinical setting. Despite testing our hypothesis in
two pathophysiologically independent models of ICH, significant
species differences and model limitations may play a role. In
particular, the collagenase model represents ‘‘deep’’ hemorrhage
formation occurring in or nearby the basal ganglia, while the laser-
rupture model more closely represents cortical microhemorrhages,
with a diameter of only 100 mm. It is difficult to extrapolate from
these models to, for example, large cortical hemorrhages in
humans. The latter frequently result from the rupture of
pathological vessels, for example arteriovenous malformations or
vessels with cerebral amyloid angiopathy, and our models of
bleeding from normal vessels cannot rule out differences in the
effects of tPA due to pre-existing vessel pathology. Furthermore,
the coagulation system of mice and humans are not entirely
comparable, as some murine factors have different roles than their
human counterparts [24]. Of course, if it would be true that
intravenous tPA does not enlarge hematomas or worsen outcomes
in ICH, then tPA could be administered at much earlier time
points to patients exhibiting signs of stroke. This could vastly
increase the effectiveness of this drug in patients with ischemic
stroke, while not worsening outcome for the patients with ICH.
However, based on clinical findings alone, it is not always possible
to distinguish patients with SAH from those with ICH. Some SAH
may mimic ICH, due to a parenchymal extension of the primary
bleeding into the lobes that surround the aneurysm [25].
According to our findings, treating a SAH patient with tPA would
have negative sequelae.
In summary, our experimental data do not support the
assumption that intravenous tPA application significantly increases
hematoma volume in acute ICH. Due to species differences and
technical limitations of the models used, our findings cannot be
immediately transferred to a clinical setting. More clinical and
experimental studies are warranted.
Methods
All experiments were performed under protocols approved by
the Massachusetts General Hospital Institutional Animal Care and
Use Committees (IACUC, protocol N-00087) and the Cornell
Institutional Animal Care and Use Committees (IACUC, protocol
2009–0043) following the NIH Guide for Use and Care of
Laboratory Animals. The ARRIVE guidelines were followed
(please see checklist below).
In-vitro tPA Activity Assay and In-vivo Reperfusion
Studies
A 96-well plate was pre-loaded with mouse plasminogen
(10 mg/ml) and the fluorogenic plasmin substrate D-Val-Leu-
Lys-7-Amino-4-Methylcoumarin (200 mM) in a final volume of
50 ml phosphate buffered saline (PBS). Thereafter, 0.125 mlo f
human recombinant tPA stock-solution (4 mg/ml) or saline was
added. In this assay, tPA converts plasminogen to plasmin, then
plasmin converts D-Val-Leu-Lys-7-Amino-4-Methylcoumarin to
a fluorescent product, which was measured over 1 hr at 5 min
intervals using a pre-warmed fluorescence plate reader (37u), with
excitation set at 360 nm and emission at 460 nm. Three measures
were performed per group and time point [6].
In-vivo thrombolytic activity of tPA was demonstrated by
a standard model of ischemic stroke based on a thromboembolic
occlusion of the middle cerebral artery in rats (see [7] for details).
In brief, one hour after initiation of ischemia, 4 animals per group
were treated intravenously with either saline or tPA (10 mg/kg).
Laser-Doppler flowmetry was used to monitor regional cerebral
blood flow for up to 150 min after treatment.
Mouse Model of Collagenase-induced Intracerebral
Hemorrhage
Experimental procedures. Experiments were performed in
male CD-1 mice (12–16 weeks) under isoflurane anesthesia,
following an institutionally approved protocol (Massachusetts
General Hospital N-00087) and in accordance with the National
Institute of Health’s Guide for the Care and Use of Laboratory
Animals. Under isoflurane anesthesia (1.5% to 2%) with sponta-
neous respiration in a nitrous oxide–oxygen mixture, the right
jugular vein was prepared. After ligating the distal part of the
vessel, a PE-10 tube was inserted into the jugular vein and moved
forward in the proximal direction. After properly fixing the tube
and closing the suture, the animals were placed in a stereotactic
frame. Under ongoing anesthesia, a small borehole was drilled,
and a 32-gauge 0.5 ml microinjection needle (Hamilton, 7000
series, Hamilton, Reno, NV, USA) was slowly lowered into the
right striatum at the following stereotactic coordinates from
bregma: 0.0 mm anterior, 2.0 mm lateral, and 3.5 mm depth.
Over a period of 5 min, 0.5 ml of saline containing 0.2 U of
Effects of tPA in Cerebral Hemorrhage
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injected [8,9]. The needle was left in place for 10 min, and then
slowly removed over a period of 5 min. Thereafter, the borehole
was sealed with bone wax and the scalp closed. The mice were
then allowed to wake up and were put in a mouse restrainer under
light restraint. Beginning 30 min or 4 hrs after hemorrhage
induction, respectively, saline (500 ml), recombinant human tPA
(10 mg/kg, diluted in 500 ml saline) or heparin (100 U/kg, diluted
in 500 ml saline) were continuously injected through the jugular
vein catheter for 30 min using an injection pump (10% bolus
injection over the first minute). The correct intravenous position of
the catheter was double-checked by drawing some blood into the
tube after the injection. The catheter was then ligated and cut near
the skin and the mice were returned to their cages.
Functional outcome and ICH volume
determination. Twenty-four hrs after hemorrhage induction,
mortality rate was determined and functional outcome was
assessed using a standard hanging wire test [8]. Afterwards, mice
were perfused with PBS and sacrificed under deep anesthesia.
Brains were removed, separated into left and right hemispheres,
and placed in glass tubes containing 3 ml PBS. After 30 sec of
homogenization, ultrasound was applied for 1 min. After centri-
fugation for 30 min (13 000 rpm, 4uC), 250 ml supernatant was
added to 1 ml Drabkins reagent. With use of a photometer,
absorption rates were determined at 540 nm, and hematoma
volumes were calculated for the entire brain (both hemispheres) on
the basis of a standard curve [8]. Mice that died within the first
24 hrs after ICH induction could not undergo perfusion. In these
cases, we subtracted 2.1 ml from the total blood volume derived
from the hemoglobin assay. This volume was found to be the
mean difference in blood content between perfused and non-
perfused brains [8].
Determining the kinetics of hematoma development. In
order to assure that the medication is administered during
hematoma formation, we sacrificed untreated mice under deep
anesthesia at 30 min (n=3), 60 min (n=4) and 24 hrs (n=1) after
hemorrhage induction. Brains were removed and cut in slices
using a 1-mm matrix to visually identify the location and size of
the hematoma (Fig. 2A). All mice showed bleeding in the right
striatum. Together with previous studies using the collagenase
model [8], these data suggested that the time interval of treatment
administration (i.e., 30 to 60 min after hemorrhage induction) well
matches the kinetics of hematoma formation.
Mouse Model of Laser-induced Parenchymal
Microhemorrhage
Experimental procedures. All animal procedures were
approved by Cornell University Institutional Animal Care and
Use Committee, following an institutionally approved protocol
(2009–43) in accordance with the National Institute of Health’s
Guide for the Care and Use of Laboratory Animals. Eleven
C57BL/6J mice (The Jackson Laboratory; 5 female, 6 male)
ranging from 21 to 32 g in mass were used to image the size of
femtosecond laser induced hemorrhages. To prepare a chronic
cranial window for imaging, mice were anesthetized using 5%
isoflurane (VetOne) and maintained at 1.5–2%. Body temperature
was kept at a constant temperature of 37.5uC with a heating
blanket and thermometer (50-7053P; Harvard Apparatus).
Glycopyrrolate (0.005 mg/kg mouse (Baxter Healthcare Corp.))
was administered intramuscularly while ketoprofen (5 mg/kg
mouse (Fort Dodge, Inc.)) and dexamethasone sodium phosphate
(0.2 mg/kg mouse (American Regent, Inc.)) were both adminis-
tered subcutaneously prior to surgery. A 6 mm diameter bilateral
craniotomy was performed over the parietal cortex. An 8 mm
glass cover slip (Deckglaser; WPI) was then glued over the exposed
brain using cyanoacrylate and dental cement (Lang Dental Mfg
Co.). Animals were administered 5% (wt/vol) glucose in physio-
logical saline (0.1 ml/100 g mice) subcutaneously and gradually
transitioned off isoflurane anesthesia. Mice were then administered
ketoprofen (5 mg/kg) every 24 hrs for 72 hrs and allowed
a minimum of five days recovery.
Two-photon excited fluorescence microscopy. Before
imaging sessions, mice were anesthetized with isoflurane and the
jugular vein was cannulated, as described above. Mice were
intravenously injected with 0.1 ml of 5% (wt/vol) lysine-fixable
Texas-red dextran (70 kDa) fluorescent dye (D1864; Invitrogen) in
physiological saline to label the vasculature. In-vivo imaging was
conducted with a locally-designed two-photon excited fluorescence
(2PEF) microscope using a 1045-nm, 1-MHz, 350-fs pulse train
from a Yb-fiber oscillator/amplifier system (mJewel FCPA, IMRA
America, Inc.) as the excitation source. Fluorescence emission was
collected with a 65 nm wide filter centered at 645 nm (Chroma).
2PEF imaging revealed surface blood vessels and sub-surface
capillaries (Fig. 3A). In addition to visualizing vascular topology,
we measured the diameter and blood flow speed and direction in
individual vessels, as described previously [26]. For hemorrhages,
we targeted cortical penetrating arterioles (PA), i.e. arterioles that
branch from the surface arteriole network and dive into the brain
to feed capillary beds [27]. These vessels were identified by tracing
through the vascular network from readily-identifiable surface
arterioles and we confirmed they were penetrating arterioles by
checking that the blood flow direction was into the brain.
Penetrating arteriole microhemorrhage by femtosecond
laser ablation. Each mouse was subjected to one to four
microhemorrhages with a minimum of 1 mm spacing between
hemorrhaged vessels. 2PEF image stacks of each microhemor-
rhage site (Fig. 3A) as well as diameter and blood flow speed
measurements of the target PAs were collected before micro-
hemorrhages were induced. A 50 ml bolus injection of saline (9
microhemorrhages across 4 animals), tPA (11 microhemorrhages
across 4 animals), or heparin (10 microhemorrhages across 3
animals) was infused through the jugular vein catheter, then after
five minutes a constant infusion (18 ml/min for 25 min) was set
using a syringe pump (PHD2000; Harvard Apparatus), as
described above.
During the period of steady infusion, the targeted PAs were
once again located and microhemorrhages were produced in the
descending segment of the PA, about 50–100 mm below the
surface of the brain. To induce a microhemorrhage, 50 fs duration
laser pulses were tightly focused (1.0 numerical aperture) on the
wall of the targeted PA, as described by Nishimura, et al [10].
Briefly, a laser energy of about 700 nJ was initially applied for a 10
pulse burst (1-kHz repetition rate). If the vessel did not rupture, the
laser energy was increased by about 50% and the vessel was
irradiated again. This process was repeated until extravasation of
red blood cells (RBC) and blood plasma into the parenchyma of
the brain was observed. The variation of required laser energy to
trigger a microhemorrhage depends mainly on the depth of the
target vessel beneath the brain surface and the presence or absence
of large blood vessels on the brain surface above the target vessel.
We use the minimum laser energy required to rupture the vessel
wall of the targeted PA and initiate bleeding into the brain. 2PEF
image stacks were taken immediately and 30 min after each PA
hemorrhage (Fig. 3A).
Red blood cell and plasma diameter
measurements. During the microhemorrhage, RBCs and
plasma exit the lumen of the targeted PA. Since the fluorescent
marker only labels blood plasma, under 2PEF imaging the RBCs
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blood plasma leaving the vessel. After the hemorrhage, the region
immediately surrounding the targeted PA is filled with RBCs [10].
This region appears dark in the 2PEF image because the RBCs are
densely packed and largely exclude the fluorescently-labeled blood
plasma (Fig. 3A). Blood plasma exiting the lumen of the target
vessel moves further into the brain parenchyma than the RBCs
and can be visualized by a ring of increased fluorescence
surrounding the RBC filled hemorrhage core. RBC hemorrhage
and plasma extravasation diameters were calculated from a max-
imal projection of 20 mm of the 2PEF image stack (ImageJ) taken
30 min after the microhemorrhage, with the stack centered on the
depth where the microhemorrhage was created. The researcher
making the diameter measurements was blinded to the treatment
group.
Post-mortem histology. At the end of each imaging session,
animals were transcardially perfused with 30 ml of phosphate
buffered saline (PBS) (Sigma-Aldrich) and 100 ml of 4% (wt/vol)
paraformaldehyde (Fisher Scientific) in PBS. The brain was
extracted from the skull and cryoprotected by immersion in 30%
(wt/vol) sucrose in PBS for 24 hrs and then in 60% sucrose in
PBS. Fiducial marks were made in the left corners of the
craniotomy window by vertically inserting a 25-gauge needle
2 mm into the brain. The needle was externally tinted with black
ink (Parker). The fiducial marks were placed in known locations
relative to the microhemorrhage sites. The brain was then frozen
and cut into 50 mm thick coronal sections on a cryostat. The
sections were mounted onto microscope slides (Superfrost Plus,
Fisher Sci.) and incubated for 12 min with diaminobenzadine
(DAB) (Peroxidase Substrate kit, Vector labs, No. SK-4100) to
stain endogenous peroxidase in RBCs and then rinsed with
deionized water. The sections were photographed under bright-
field and fluorescence microscopy. Fiducials were mapped and
used to identify the slices and location within slices where
microhemorrhages were located. Microhemorrhages were identi-
fied on the basis of both DAB stained RBCs and Texas red-
dextran fluorescence in the parenchymal space (Fig. S2A–C).
Penetrating arteriole volume blood flux and laser energy
used to make hemorrhage do not influence hemorrhage
sizes. We tested whether there was any correlation between the
measured RBC and plasma extravasation diameters and the
volume blood flux of the targeted PA or the laser energy used to
trigger the microhemorrhage. Within the range of laser energies
and PA blood fluxes studied here, there were no significant
correlations between the RBC and plasma diameters with
penetrating arteriole flux rates or deposited energy across all
three treatment groups (Pearson product-moment correlation
coefficient for RBC hemorrhage diameter, Spearman’s rank
correlation coefficient for plasma diameter).
Mouse Model of Subarachnoid Hemorrhage
Experimental procedures. In male CD-1 mice, isoflurane
anesthesia (1.5% to 2%) was induced with spontaneous respiration
in a nitrous oxide–oxygen mixture. A heating pad was used to
maintain the body temperature at 37.060.5uC. A blunted 4–
0 monofilament nylon suture was introduced into the external
carotid artery and advanced through the internal carotid artery to
the left anterior cerebral artery (ACA) near the anterior
communicating artery, where resistance was encountered and
a severe decrease was seen in cerebral blood flow. The filament
was advanced 3 to 5 mm further to perforate the ACA, then
immediately withdrawn. SAH was confirmed by the persistence of
reduction in CBF [11]. Then, the right jugular vein was prepared
and the catheter for drug infusion was inserted as described above.
Thirty min after SAH induction, saline or tPA was infused as
described above.
Functional outcome and quantification of subarachnoid
blood volume. Twenty-four hrs after SAH induction, mortality
and functional outcome was assessed using a modified 18-point
scoring system in a blinded fashion [28]. Subarachnoid blood
volume was also assessed by means of a previously published
photometric hemoglobin assay method, with slight modifications
[28,29]. In brief, mice were perfused using PBS and sacrificed
under deep anesthesia. Brains were dissected and removed with
the dura intact to avoid the loss of any subarachnoid blood, and
whole brain placed in glass tubes containing 3 ml PBS.
Hemoglobin content was measured as described above. Mice that
died within the first 24 hrs after SAH induction could not undergo
perfusion. In these cases, we subtracted 2.1 ml from the total blood
volume derived from the hemoglobin assay, as described above.
SDS-PAGE Gelatin Zymography
Gelatin zymograms were used to measure the levels of MMP-2
and MMP-9 in brain homogenates from ICH mice and from mice
that underwent focal cerebral ischemia as described elsewhere in
detail [30,31]. For the ICH group, mice were treated with saline
(n=5) or 10 mg/kg tPA (n=5) intravenously at 3 hrs after
collagenase injection. Following transcardial perfusion with ice-
cold PBS under deep anesthesia, brains were extracted at 6 hrs
after ICH induction. For the ischemia group, the middle cerebral
arteries were occluded with intraluminal sutures for 3 hrs. At the
time point of reperfusion, mice were treated with saline (n=5) or
10 mg/kg tPA (n=5) intravenously. Brains were extracted after
3 hrs of reperfusion. Brains were divided into ipsilateral and
contralateral hemispheres, then frozen immediately in liquid
nitrogen and stored at 280uC. Samples were homogenized in lysis
buffer including protease inhibitors on ice. After centrifugation,
supernatant was collected, and total protein concentrations were
determined using the Bradford assay (Bio-Rad). Prepared protein
samples were loaded and separated by 10% Tris-glycine gel with
0.1% gelatin as substrate. MMP activity was quantified via
standard densitometry. MMP indexes were calculated based on
purified MMP-2 and -9 standards.
Statistical Analysis
Statistical analysis was performed using SPSS 19.0 (IBM,
Armonk, NY) and StatsDirect v.2.7.8 (Cheshire, UK). Data were
tested for normality and variance homogeneity. We used one-way
ANOVA to determine if there were differences across the three
treatment groups. If statistically significant differences were found
by ANOVA, we performed pair-wise comparisons between groups
using the Bonferroni multiple-comparisons correction. Depending
on scale level and data distribution, t-test or Mann Whitney U-test
were used to compare means between two groups, respectively. p-
values less than 0.05 were considered statistically significant.
Supporting Information
Figure S1 Functional outcome 24 hrs after ICH induction was
assessed by means of a standard hanging wire test (time to fall-off,
maximum 60 sec, three attempts per mouse). No difference was
observed between saline- and tPA-treated mice.
(TIF)
Figure S2 Representative coronal post-mortem tissue sections of
microhemorrhages from animals treated with saline (a, d), tPA
(b, e) or heparin (c, f). Panels (a-c) show white-light transmission
images of DAB treated sections, which show the RBCs that have
hemorrhaged into the tissue as black. Panels (d-f) show
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same sections as panels (a-c).
(TIF)
Figure S3 Gelatin zymography of MMP responses. Represen-
tative zymogram gels showing MMP-2 and MMP-9 levels in brain
homogenates derived from middle cerebral artery occlusion
(MCAO) (A) or primary ICH (B) mice. In both MCAO and
ICH models, MMP-2/29 levels on the contralateral side were not
affected by tPA treatment, indicating that tPA treatment does not
change MMP-2/29 baseline levels. In contrast, in MCAO mice,
MMP levels on the ipsilateral side were increased by tPA
treatment (see Fig. 5 for more details).
(TIF)
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